目的 探讨肝爽颗粒联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎的临床效果。方法 选取2016年1月-2016年9月在宝鸡市中医医院接受治疗的84例慢性乙型肝炎患者为研究对象，根据治疗方案的差别分为对照组（42例）和治疗组（42例）。对照组患者皮下注射聚乙二醇干扰素α-2a注射液0.5 mL，1次/周。治疗组患者在对照组的基础上口服肝爽颗粒，3 g/次，3次/d。两组患者均治疗3个月。评价两组患者临床疗效，同时比较治疗前后两组患者肝功能以及血清白介素-17 （IL-17）、巨噬细胞移动抑制因子（MIF）和HBV-DNA水平。结果 治疗后，对照组和治疗组总有效率分别为80.95%、95.24%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肝功能丙氨酸氨基转移酶（ALT）、门冬氨酸转氨酶（AST）、总胆红素（TBIL）水平以及IL-17、MIF和HBV-DNA水平均显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者上述观察指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肝爽颗粒联合聚乙二醇干扰素α-2a治疗慢性乙型肝炎可有效改善机体肝功能和血清IL-17、MIF和HBV-DNA水平，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Ganshuang Granules combined with peginterferon α-2a in treatment of chronic hepatitis B. Methods Patients (84 cases) with chronic hepatitis B in Baoji City Hospital of TCM from January 2016 to September 2016 were divided into control (42 cases) and treatment (42 cases) groups according to different treatments. Patients in the control group were subcutaneous injection administered with Peginterferon α-2a Solution for injection, 0.5 mL/time, once weekly. Patients in the treatment group were po administered with Ganshuang Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the liver function, serum IL-17, MIF, and HBV-DNA level in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.95% and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, the ALT, AST, TBIL, IL-17, MIF and HBV-DNA level in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these observation indexes in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ganshuang Granules combined with peginterferon α-2a can significantly improve the liver function and serum IL-17, MIF and HBV-DNA level in treatment of chronic hepatitis B, which has a certain clinical application value.